Literature DB >> 23649911

The role of radiation in retroperitoneal sarcomas.

Pranshu Mohindra1, Heather B Neuman, Kevin R Kozak.   

Abstract

OPINION STATEMENT: Retroperitoneal sarcomas form a group of rare malignancies that require expertise in every aspect of management. Patients benefit from referral to cancer centers that can provide comprehensive, multidisciplinary, oncologic management. The role of radiation in retroperitoneal sarcoma management is, appropriately, the subject of considerable controversy due to the absence of high-level evidence proving its efficacy. Nonetheless, the preponderance of available data suggests that radiation therapy likely improves local control and, in some settings, may favorably impact resectability and survival. These outcome observations coupled with the lower doses (45-54 Gy) and normal tissue displacement characteristic of preoperative radiation therapy leads us to favor preoperative radiotherapy followed by oncologic resection for most retroperitoneal sarcomas. This strategy appears to provide the highest chance of safe and successful delivery of multimodal therapy, which can otherwise be hindered by postoperative complications as a result of technically challenging surgery and normal tissue radiation dose tolerances. Dose-escalation and selective integrative boosts to "at-risk" margins are attractive strategies that merit, and arguably require, further clinical evaluation. We believe that postoperative radiotherapy should be reserved for very high-risk cases and should be treated to a dose of ≥60 Gy respecting normal tissue dose tolerances. An additional approach that we consider in the postoperative setting is close surveillance with consideration of preoperative radiotherapy at recurrence before repeat surgical resection. Highly conformal radiotherapy techniques, such as IMRT with image guidance, should be employed to minimize dose to normal tissues and thereby allow delivery of efficacious radiation doses. If feasible, referral to a treatment facility with proton beam therapy should be discussed with the patient, especially if normal tissue dose constraints cannot be met using IMRT/IGRT. Participation in prospective studies should be highly encouraged.

Entities:  

Mesh:

Year:  2013        PMID: 23649911      PMCID: PMC3769487          DOI: 10.1007/s11864-013-0236-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  56 in total

1.  Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma.

Authors:  Ching-Wei D Tzeng; John B Fiveash; Richard A Popple; J Pablo Arnoletti; Suzanne M Russo; Marshall M Urist; Kirby I Bland; Martin J Heslin
Journal:  Cancer       Date:  2006-07-15       Impact factor: 6.860

Review 2.  A systematic review of the impact of volume of surgery and specialization on patient outcome.

Authors:  M M Chowdhury; H Dagash; A Pierro
Journal:  Br J Surg       Date:  2007-02       Impact factor: 6.939

3.  Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma.

Authors:  Robert Krempien; Falk Roeder; Susanne Oertel; Jürgen Weitz; Frank W Hensley; Carmen Timke; Angela Funk; Katja Lindel; Wolfgang Harms; Markus W Buchler; Jürgen Debus; Martina Treiber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-06       Impact factor: 7.038

Review 4.  Retroperitoneal tumours: review of management.

Authors:  Dirk C Strauss; Andrew J Hayes; J Meirion Thomas
Journal:  Ann R Coll Surg Engl       Date:  2011-05       Impact factor: 1.891

5.  Postoperative nomogram for 12-year sarcoma-specific death.

Authors:  Michael W Kattan; Denis H Y Leung; Murray F Brennan
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

Review 6.  Radiotherapy and surgery-an indispensable duo in the treatment of retroperitoneal sarcoma.

Authors:  Lien Van De Voorde; Louke Delrue; Marc van Eijkeren; Gert De Meerleer
Journal:  Cancer       Date:  2011-03-28       Impact factor: 6.860

7.  A decade of mortality reductions in major oncologic surgery: the impact of centralization and quality improvement.

Authors:  Peter A Learn; Peter B Bach
Journal:  Med Care       Date:  2010-12       Impact factor: 2.983

8.  Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control.

Authors:  Sylvie Bonvalot; Michel Rivoire; Marine Castaing; Eberhard Stoeckle; Axel Le Cesne; Jean Yves Blay; Agnès Laplanche
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

9.  Retroperitoneal sarcoma: the University of Florida experience.

Authors:  J W Kilkenny; K I Bland; E M Copeland
Journal:  J Am Coll Surg       Date:  1996-04       Impact factor: 6.113

10.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Authors:  Robert G Maki; J Kyle Wathen; Shreyaskumar R Patel; Dennis A Priebat; Scott H Okuno; Brian Samuels; Michael Fanucchi; David C Harmon; Scott M Schuetze; Denise Reinke; Peter F Thall; Robert S Benjamin; Laurence H Baker; Martee L Hensley
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

View more
  5 in total

1.  Role of radiation therapy for retroperitoneal sarcomas: An eight-institution study from the US Sarcoma Collaborative.

Authors:  Konstantinos Chouliaras; Rebecca Senehi; Cecilia G Ethun; George Poultsides; Valerie Grignol; Callisia N Clarke; Kevin K Roggin; Ryan C Fields; Patrick B Schwartz; Sean M Ronnekleiv-Kelly; Ralph D'Agostino; Emily N Johnson; Edward A Levine; Kenneth Cardona; Konstantinos I Votanopoulos
Journal:  J Surg Oncol       Date:  2019-09-04       Impact factor: 3.454

2.  Primary psoas sarcoma causing malignant psoas syndrome: favourable response to radiotherapy.

Authors:  Thomas A McKay; Sarah Bishop; Michael J McKay
Journal:  Ann Transl Med       Date:  2017-03

3.  Aggressive Surgical Approach for Treatment of Primary and Recurrent Retroperitoneal Soft Tissue Sarcoma.

Authors:  Antonio Chiappa; Emilio Bertani; Gabriella Pravettoni; Andrew Paul Zbar; Diego Foschi; Giuseppe Spinoglio; Bernardo Bonanni; Gianluca Polvani; Federico Ambrogi; Maria Laura Cossu; Carlo Ferrari; Marco Venturino; Cristiano Crosta; Luca Bocciolone; Roberto Biffi
Journal:  Indian J Surg       Date:  2018-01-31       Impact factor: 0.656

4.  Retroperitoneal soft-tissue sarcomas: Radiotherapy experience from a tertiary cancer center and review of current evidence.

Authors:  A Montero; M Nuñez; O Hernando; E Vicente; R Ciervide; D Zucca; E Sanchez; M López; Y Quijano; M Garcia-Aranda; R Alonso; J Valero; X Chen; B Alvarez; P Fernandez-Leton; C Rubio
Journal:  Rep Pract Oncol Radiother       Date:  2020-06-09

Review 5.  Retroperitoneal liposarcoma: current insights in diagnosis and treatment.

Authors:  Lucas E Matthyssens; David Creytens; Wim P Ceelen
Journal:  Front Surg       Date:  2015-02-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.